|Articles|March 16, 2021
HIC Analysis of Drug-to-Antibody Ratio
Author(s)Agilent Technologies, Inc.
This application note demonstrates the DAR determination of brentuximab vedotin using HIC. Excellent reproducibility was found with the Agilent 1290 Infinity II Bio LC.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
FDA Clears PharmaResearch IND for Nano-Based Cancer Drug PRD-101
5